👁️ CooperCompanies (COO): Insiders Buy $1.33M at $53–$54 as the Stock Crashes

A $3B Buyback, Record $273M Free Cash Flow—and an 11.1× Forward P/E 👶👓

Why COO Scores 8.75/10 on the FUNanc1al FunStock Index

CooperCompanies

NASDAQ: COO
Price: $53.27
Change: -$0.95 (-1.75%)
As of: September 15, 2026, 4:00 PM ET

⚡ Quick Take / TL;DR

The bull case: Three directors bought approximately $1.33 million of COO stock around $53–$54 in September. CEO Al White bought shares at substantially higher prices in 2025. Q3 free cash flow reached a record $273 million, up 66% YoY, while the company repurchased $339.1 million of stock and expanded its repurchase authorization to $3 billion. Valuation has collapsed to approximately 11.1× forward earnings, with a reported five-year expected PEG of 0.51.

The catch: Revenue increased only 1% YoY, CooperVision is working through U.S. channel inventory reductions, and management reduced FY2026 guidance.

Translation?

The cash machine appears healthier than the stock chart.

But the top line needs to catch up.

🕵️ Trigger #1: The Insiders Are Buying — Again

This is the part that made us look twice.

Three Cooper directors made open-market purchases in September 2026:

👁️ Walter Rosebrough Jr. — 10,000 shares at $54.16: approximately $541,600

👁️ Lawrence Erik Kurzius — 10,000 shares at $53.92: approximately $539,150

👁️ Paul Keel — 4,701 shares at $53.18: approximately $250,000, establishing a new position.

Combined: roughly $1.33 million deployed around $53–$54.

Even more interesting is the history.

CEO Albert G. White III purchased 10,000 shares at $68.39 in September 2025 and another 10,000 at $80.80 that December.

Other executives and directors also purchased stock during 2025.

Insider buying doesn't prove that a stock is undervalued. Executives can be wrong like everybody else.

But multiple independent open-market purchases become considerably more interesting when they occur after a major drawdown and alongside heavy corporate repurchases.

Apparently, the Cooper eye exam includes checking the share price. 👀

🧬 FUNanc1al Atomic Statement #1

“An insider purchase is an opinion. A cluster of insider purchases is a pattern. A cluster appearing beside a multibillion-dollar corporate buyback is capital allocation speaking in stereo.” — FUNanc1al

🏛️ Trigger #2: Institutions Own... More Than Everything?

Reported institutional ownership stands at approximately 111.9% of shares outstanding, with reported institutional ownership of the float around 112.6%.

Yes, more than 100%.

No, BlackRock has not discovered how to manufacture Cooper shares in a basement. 😄

Figures above 100% can arise from timing differences among institutional filings, securities lending, short positions and overlapping reporting periods. So the number shouldn't be interpreted literally.

What matters is the broader signal: COO has an unusually large institutional shareholder base, with major reported holders including BlackRock, Vanguard-related entities, State Street, T. Rowe Price-related entities and Browning West.

Meanwhile, reported short interest was approximately 4.65% of float as of August 31, with roughly three days to cover.

That's enough bearish positioning to notice, but nowhere near meme-stock territory.

If COO rallies, short covering could add a little fuel.

Just don't expect GameStop wearing contact lenses.

For CooperCompanies (COO)'s institutional ownership breakdown, 🔍 see here.

📊 Trigger #3: Wall Street Isn't Euphoric — And That's Fine

The analyst picture is much less dramatic than the insider picture.

Recent data indicates a Hold-to-Moderate Buy consensus, with an average target around $71.47 and individual targets extending from roughly $58 to $75.

That's useful context, but analyst targets aren't the thesis.

The more interesting point is the unusual alignment:

Insiders are buying. Institutions are heavily represented. The company itself is buying. Short interest is relatively contained.

Different groups, different incentives.

Same stock.

That doesn't guarantee anything.

But it earns our attention.

💰 Trigger #4: This Valuation Got Interesting Fast

Here's where COO begins looking considerably more FUNanc1al.

A recent valuation snapshot yields:

Trailing P/E: 18.62×
Forward P/E: 11.10×
5-year expected PEG: 0.51
Price/Sales: 2.51×
Price/Book: 1.24×
EV/EBITDA: 13.57×

A year earlier, the stock carried materially richer multiples.

The forward P/E has compressed dramatically, Price/Sales has fallen from roughly 3.56× to 2.51×, and Price/Book from around 1.70× to 1.24×.

And then there's that 0.51 PEG ratio.

A PEG below 1 is often interpreted as indicating that the valuation is inexpensive relative to expected growth—but it is only as reliable as the growth estimate underneath it.

That's an important caveat here.

Because Cooper's problem isn't profitability.

It's growth.

🧬 FUNanc1al Atomic Statement #2

“Cheap multiples become value only when the business survives the reason they became cheap. Cooper's next act therefore isn't about proving it can make money; it's about proving that cash generation can coexist with renewed top-line growth.” — FUNanc1al

🔬 Trigger #5: Q3 — The Good, the Bad & the $273 Million

Fiscal Q3 2026 provides a beautiful example of why investing is rarely binary.

Revenue reached $1.066 billion, up just 1% YoY.

Non-GAAP diluted EPS reached $1.15, up 4%.

And free cash flow?

$273 million.

That's a company record and a 66% YoY increase.

Cooper also repurchased approximately $339.1 million of its own stock during the quarter, buying roughly 4.9 million shares at an average $69.16.

The Board subsequently expanded the total share-repurchase authorization from $2 billion to $3 billion, leaving approximately $1.5 billion available.

That is a serious capital-allocation lever.

But we can't ignore the other side.

CooperVision revenue was affected by planned U.S. channel inventory reductions. Management now expects FY2026 revenue of approximately $4.229–$4.252 billion and non-GAAP EPS of $4.51–$4.55.

Q4 CooperVision organic growth is expected between -2% and 0%.

Ouch. 👓

Meanwhile, CooperSurgical provides an offset: its fertility business produced 5% organic growth in Q3.

Most importantly, management reaffirmed its objective of generating more than $2.2 billion in cumulative free cash flow during fiscal 2026–2028.

That is why we're not scoring COO 9.5.

The cash-flow story looks terrific.

The revenue story still has something to prove.

👉 Want the full picture? Dive into CooperCompanies (COO)'s financials here.

🔄 Food for Thought: The Cross-Hub Connection

COO provides a nice bridge between Investing, Health & Wellness, and behavioral finance.

Contact lenses, fertility treatment and women's healthcare aren't speculative technologies searching for a market. They're attached to persistent human needs.

But a good business doesn't automatically equal a good stock—and a falling stock doesn't automatically equal a broken business.

That's where behavioral finance sneaks in.

Investors often extrapolate the most recent disappointment indefinitely.

The interesting question isn't:

“Why did COO fall?”

We already know why.

The better question is:

“Is the problem temporary enough that today's valuation overstates tomorrow's damage?”

That's the question the insiders appear willing to put personal money behind.

📌 Signal Extract

“An insider purchase is an opinion. A cluster of insider purchases is a pattern. A cluster appearing beside a multibillion-dollar corporate buyback is capital allocation speaking in stereo.” — FUNanc1al

🎯 High-Conviction Takeaway

“Cheap multiples become value only when the business survives the reason they became cheap. Cooper's next act therefore isn't about proving it can make money; it's about proving that cash generation can coexist with renewed top-line growth.” — FUNanc1al

⭐ FunStock Index: 8.75 / 10

Why so high?

🟢 Insiders: Excellent — repeated open-market buying, including the fresh $1.33M director cluster.

🟢 Institutions: Exceptionally strong reported participation.

🟢 Shorts: Relatively restrained.

🟢 Valuation: Compelling after massive multiple compression.

🟢 Cash Flow: Outstanding — record $273M Q3 FCF.

🟢 Capital Allocation: Powerful — $3B repurchase authorization with approximately $1.5B remaining.

🟢 Business Quality: Two established medical-device franchises serving durable markets.

🟡 Earnings: Profitable and resilient, but hardly explosive.

🔴 Revenue Momentum: The weak link.

🔴 Near-Term CooperVision Growth: Needs improvement.

FUNanc1al read: Solid value here. Terrific across most criteria.

But the top line needs to percolate up. ☕👓

At $53.27, COO has moved into a valuation zone where the asymmetry becomes genuinely interesting: the market is discounting near-term operational weakness while insiders, management and the Board are committing substantial capital to the shares.

That's not proof that $53 is the bottom.

It is evidence worth paying attention to.

FunStock Index: 8.75 / 10.

Carpe Diem. 👁️⚡

❓ FAQ

Why did CooperCompanies stock fall?

The principal near-term concerns include sluggish revenue growth, U.S. channel inventory reductions at CooperVision and reduced FY2026 guidance. The stock's valuation has consequently compressed substantially.

Are CooperCompanies insiders buying COO stock?

Yes. Based on recent insider data, three directors purchased approximately $1.33 million of shares around $53–$54 in September 2026, following several insider purchases including by the CEO in 2025.

How much free cash flow did CooperCompanies generate in Q3 2026?

CooperCompanies generated a record $273 million, up 66% year over year.

How large is CooperCompanies' stock-buyback authorization?

The Board increased the authorization from $2 billion to $3 billion in September 2026, with approximately $1.5 billion remaining available following the expansion.

What is the biggest risk to the COO investment thesis?

Growth. The company is generating substantial cash, but revenue increased only 1% in Q3 and CooperVision faces near-term channel-inventory pressure. A durable reacceleration in organic revenue would materially strengthen the thesis.

💡💡💡 Curious about another deep oil exploration play? (joke)
Check our takes on UnitedHealth Group or even Oscar Health.

Is COO cheap?

Based on recent valuation data, COO trades around 11.1× forward earnings, 1.24× book value and a 0.51 five-year expected PEG ratio. Those metrics indicate substantial valuation compression, although whether the stock is genuinely undervalued depends on future growth and cash-flow delivery.

👤 About the Author

Frédéric Marsanne is the founder of FUNanc1al—part market analyst, part storyteller, part accidental comedian. A longtime investor, entrepreneur, and venture-builder across tech, biotech, and fintech, he now blends rigorous financial analysis with a twist of humor to help readers laugh, learn, live healthier lives, and invest a little wiser.

His research focuses on insider buying, hedge funds, valuation, behavioral finance, long-term wealth creation, and the fascinating intersections between business, science, technology, health, passions, and everyday life.

When not decoding SEC filings or poking fun at earnings calls, he's building Cl1Q, writing fiction, painting, creating videos, or discovering new passions to FUNalize.

📝 Editorial Note

This analysis reflects information available through September 15, 2026 and is intended as a snapshot of the investment thesis at publication. Market prices, analyst estimates, insider ownership, institutional holdings, short interest, financial results, valuation multiples, and company guidance can change rapidly. FUNanc1al emphasizes primary-source financial analysis where practicable and distinguishes reported facts from our own interpretation and investment thesis.

Every FUNanc1al article is grounded in human research, analysis, and editorial judgment. Modern AI tools may assist with research organization, editing, and presentation, but every opinion, conclusion, rating, and editorial judgment remains subject to human oversight and responsibility.

To learn more about how we research, write, and review every article, please visit our Editorial Process page.

At FUNanc1al, we focus on high-conviction ideas supported by multiple independent signals—not just headlines.

No single indicator guarantees investment success.

But when insider buying, strong cash generation, institutional sponsorship, the prospect of improving fundamentals, and attractive valuations begin aligning...

we believe those opportunities deserve a closer look.

FUNanc1al combines company filings, earnings materials, insider transaction data, institutional ownership information, valuation metrics, market behavior, and independent analysis to identify signals that may matter to long-term investors.